Home/Filings/4/0001683168-23-000432
4//SEC Filing

Mehalick David 4

Accession 0001683168-23-000432

CIK 0001759186other

Filed

Jan 30, 7:00 PM ET

Accepted

Jan 31, 10:59 AM ET

Size

9.3 KB

Accession

0001683168-23-000432

Insider Transaction Report

Form 4
Period: 2023-01-27
Mehalick David
DirectorCEO and President10% Owner
Transactions
  • Award

    Incentive Stock Options (right to buy)

    2023-01-27+250,000250,000 total
    Exercise: $1.76Common Stock (250,000 underlying)
  • Award

    Non-qualified Stock Options (right to buy)

    2023-01-27+375,000375,000 total
    Exercise: $1.60Common Stock (375,000 underlying)
Footnotes (10)
  • [F1]On January 27, 2023, the reporting person received a grant of 375,000 stock options, as non-qualified options, under the 2022 equity incentive plan.
  • [F10]Following the exercise of options under both reported transactions, the reporting person will have a total of 625,000 derivative securities beneficially owned.
  • [F2]On January 27, 2023, the reporting person received a grant of 250,000 incentive stock options, under the 2022 equity incentive plan.
  • [F3]Options will vest over 4 years, with the first 25% vesting on 12/31/23, and the balance vesting in equal quarterly installments over the succeeding three years, with the final options vesting on 12/31/26.
  • [F4]Options will vest over 4 years, with the first 25% vesting on 12/31/23, and the balance vesting in equal quarterly installments over the succeeding three years, with the final options vesting on 12/31/26.
  • [F5]The exercise price is the FMV of the shares, which is equal to the Company's stock price on the Nasdaq Global Market on the day of grant.
  • [F6]The exercise price is equal to 110% of the FMV of the shares on the day of grant.
  • [F7]Expiration date is ten years from the day of grant
  • [F8]Expiration date is five years from the day of grant, as the reporting person is a 10% owner and the options are incentive stock options.
  • [F9]Following the exercise of options under both reported transactions, the reporting person will have a total of 625,000 derivative securities beneficially owned.

Documents

1 file

Issuer

Coeptis Therapeutics Holdings, Inc.

CIK 0001759186

Entity typeother

Related Parties

1
  • filerCIK 0001846623

Filing Metadata

Form type
4
Filed
Jan 30, 7:00 PM ET
Accepted
Jan 31, 10:59 AM ET
Size
9.3 KB